Citigroup’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.4M | Buy |
714,000
+514,867
| +259% | +$9.13M | ﹤0.01% | 1590 |
|
|
2026
Q1 | $3.78M | Buy |
199,133
+69,207
| +53% | +$1.12M | ﹤0.01% | 2180 |
|
|
2025
Q4 | $2.27M | Sell |
129,926
-29,947
| -19% | -$563K | ﹤0.01% | 2568 |
|
|
2025
Q3 | $3.3M | Buy |
159,873
+46,535
| +41% | +$1.13M | ﹤0.01% | 2288 |
|
|
2025
Q2 | $2.41M | Sell |
113,338
-182,077
| -62% | -$4.15M | ﹤0.01% | 2474 |
|
|
2025
Q1 | $5.7M | Buy |
295,415
+41,375
| +16% | +$830K | ﹤0.01% | 1785 |
|
|
2024
Q4 | $4.53M | Buy |
254,040
+177,905
| +234% | +$3.45M | ﹤0.01% | 2069 |
|
|
2024
Q3 | $1.67M | Buy |
76,135
+12,560
| +20% | +$176K | ﹤0.01% | 2819 |
|
|
2024
Q2 | $496K | Sell |
63,575
-495,431
| -89% | -$2.68M | ﹤0.01% | 3404 |
|
|
2024
Q1 | $2.31M | Buy |
559,006
+529,869
| +1,819% | +$2.11M | ﹤0.01% | 2325 |
|
|
2023
Q4 | $76K | Buy |
29,137
+20,079
| +222% | +$41.3K | ﹤0.01% | 4322 |
|
|
2023
Q3 | $16.9K | Sell |
9,058
-40,786
| -82% | -$77.8K | ﹤0.01% | 4437 |
|
|
2023
Q2 | $125K | Sell |
49,844
-10,128
| -17% | -$18.5K | ﹤0.01% | 4134 |
|
|
2023
Q1 | $105K | Buy |
59,972
+4,622
| +8% | +$12.6K | ﹤0.01% | 3998 |
|
|
2022
Q4 | $235K | Buy |
55,350
+52,801
| +2,071% | +$96K | ﹤0.01% | 3637 |
|
|
2022
Q3 | $3K | Buy |
2,549
+829
| +48% | +$938 | ﹤0.01% | 5416 |
|
|
2022
Q2 | $2K | Sell |
1,720
-1,570
| -48% | -$2.2K | ﹤0.01% | 5916 |
|
|
2022
Q1 | $8K | Sell |
3,290
-7,212
| -69% | -$18.2K | ﹤0.01% | 5642 |
|
|
2021
Q4 | $28K | Buy |
10,502
+1,507
| +17% | +$7.24K | ﹤0.01% | 5295 |
|
|
2021
Q3 | $45K | Buy |
8,995
+1,830
| +26% | +$13.1K | ﹤0.01% | 4793 |
|
|
2021
Q2 | $53K | Sell |
7,165
-8,167
| -53% | -$53.6K | ﹤0.01% | 4794 |
|
|
2021
Q1 | $90K | Buy |
15,332
+12,658
| +473% | +$81.7K | ﹤0.01% | 4417 |
|
|
2020
Q4 | $13K | Buy |
2,674
+2,474
| +1,237% | +$10.5K | ﹤0.01% | 6872 |
|
|
2020
Q3 | $1K | Hold |
200
| – | – | ﹤0.01% | 7384 |
|
|
2020
Q2 | $1K | Hold |
200
| – | – | ﹤0.01% | 7475 |
|
|
2020
Q1 | $0 | Hold |
200
| – | – | ﹤0.01% | 7760 |
|
|
2019
Q4 | $0 | Hold |
200
| – | – | ﹤0.01% | 7791 |
|
|
2019
Q3 | $0 | Hold |
200
| – | – | ﹤0.01% | 7808 |
|
|
2019
Q2 | $0 | Hold |
200
| – | – | ﹤0.01% | 7845 |
|
|
2019
Q1 | $0 | Hold |
200
| – | – | ﹤0.01% | 7789 |
|
|
2018
Q4 | $0 | Hold |
200
| – | – | ﹤0.01% | 7820 |
|
|
2018
Q3 | $0 | Hold |
200
| – | – | ﹤0.01% | 7857 |
|
|
2018
Q2 | $0 | Hold |
200
| – | – | ﹤0.01% | 7722 |
|
|
2018
Q1 | $3K | Hold |
200
| – | – | ﹤0.01% | 7314 |
|
|
2017
Q4 | $2K | Hold |
200
| – | – | ﹤0.01% | 7396 |
|
|
2017
Q3 | $3K | Buy |
+200
| New | +$2.59K | ﹤0.01% | 6966 |
|
|
2015
Q3 | – | Sell |
-53
| Closed | -$1K | – | 7683 |
|
|
2015
Q2 | $1K | Buy |
+53
| New | +$600 | ﹤0.01% | 7331 |
|
Other funds holding SMMT
BBA
Citigroup's SMMT Position: Q2 2026 in Review
Citigroup increased its Summit Therapeutics (SMMT) stake by 259% in Q2 2026, buying an estimated $9.13M and bringing the position to 714,000 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1590.
Citigroup first reported a position in SMMT in Q2 2015 and has held it in 37 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.
- Citigroup held 714,000 shares of Summit Therapeutics worth $10.4M as of Q2 2026.
- Citigroup bought 514,867 Summit Therapeutics shares in Q2 2026, an estimated $9.13M.
- Summit Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1590 holding.
- Citigroup first reported a position in Summit Therapeutics in Q2 2015 and has held it in 37 quarters since.
- 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.